Roy Whitfield has been a director since January 2007. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation (formerly Incyte Genomics), a drug discovery and development company he co-founded in 1991. From 1993 to 2001, Whitfield served as its Chief Executive Officer and, from November 2001 until his retirement in June 2003, as its Chairman. Whitfield remains on the board of Incyte Corporation. From 1984 to 1989, Roy held senior operating and business development positions with Technicon Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Earlier, Whitfield spent seven years with the Boston Consulting Group's international consulting practice. In addition to serving on the Incyte Board, he is a director of Nektar Therapeutics, a clinical-stage biopharmaceutical company.
Whitfield received a B.S. in Mathematics from Oxford University and an M.B.A. from Stanford University.